Market Overview

Symposium to Explore the Impact of Vascular Dissections on Critical Limb Ischemia Patients at AMP 2018

Share:

A Case-Based Look at Below-the-Knee Lesions Post-Angioplasty

Intact Vascular, Inc., a developer of medical devices for minimally
invasive peripheral vascular procedures, today announced key
presentations that will be featured during a CME symposium at the
Amputation Prevention (AMP) Conference in Chicago on August 8.

The symposium, titled "Why Dissections Matter: A case-based look at
below-the-knee lesions post-PTA" will explore how post-percutaneous
transluminal angioplasty (PTA) dissections are often overlooked,
underdiagnosed and left untreated. These dissections can compromise
clinical outcomes in both the short and long term, thus putting limbs at
increased risk of reduced blood flow, gangrene and amputation. The
symposium will feature three critical limb ischemia experts: George
Adams, MD, Marianne Brodmann, MD and Peter Soukas, MD.

"The effect of post-angioplasty dissection in lower extremities, or
below-the-knee, is particularly detrimental in patients with critical
limb ischemia," said George Adams, M.D., M.H.S., Director of
Cardiovascular and Peripheral Vascular Research, UNC REX Hospital,
Raleigh, N.C. "The ability to properly identify and treat these
dissections is essential to preserving blood flow and preventing
amputation in this vulnerable patient population."

Intact Vascular's Tack Endovascular System® is a new solution
for precision dissection repair following balloon angioplasty with a
first-of-its-kind implant that is designed to help maintain vessel
integrity and enhance blood flow to promote healing, improve outcomes
and preserve limbs. The Tack Endovascular System leaves a minimal amount
of metal in the artery, reduces mechanical stress on the arterial wall
and preserves future treatment options.

Intact Vascular is sponsoring three clinical trials to evaluate its Tack
Endovascular System: TOBA II, TOBA II BTK and TOBA III. TOBA II is
investigating the combination of the Tack implant with both plain
angioplasty balloons and the BARD Lutonix® drug-coated
balloon (DCB) in the arteries above the knee, and completed enrollment
in March 2017. TOBA II BTK is investigating the combination of the Tack
implant with plain balloon angioplasty in the arteries below the knee
and is actively enrolling patients. TOBA III has completed enrollment in
Europe and is investigating the combination of the Tack implant with the
Medtronic IN.PACT™ Admiral™ (DCB), inclusive of long lesions.

About Intact Vascular

Intact Vascular is a privately held medical device company that develops
minimally- invasive peripheral vascular products. The Tack Endovascular
System is designed to improve peripheral balloon angioplasty results in
the treatment of peripheral arterial disease. Visit www.intactvascular.com
for more information.

This press release contains "forward-looking statements" concerning the
development of Intact Vascular's products, the potential benefits and
attributes of such products, and the company's expectations regarding
its prospects. Forward-looking statements are subject to risks,
assumptions and uncertainties that could cause actual future events or
results to differ materially from such statements. These statements are
made as of the date of this press release. Actual results may vary.
Intact Vascular undertakes no obligation to update any forward-looking
statements for any reason.

Tack Endovascular System® is a trademark of Intact Vascular, Inc.
Lutonix®
is a trademark of C.R. BARD, Inc.
IN.PACT(TM) Admiral(TM) are
trademarks of Medtronic.

"CAUTION: Investigational device. Limited by Federal (United
States) law to investigational use."
The Tack Endovascular
System® is CE Mark Authorized under EC Directive 93/42/EEC.
Not
available for sale or use in the United States.

View Comments and Join the Discussion!